On November 16, SKB BIO fell 3.04% in Regular Trading, trading at HK$434.4, with turnover of HK$62.10 million.
The clearest recent catalyst is an investment-bank update: a major broker raised its target price to HK$645.62 and maintained a Buy rating, but the positive call did not prevent the stock from remaining under near-term selling pressure.
According to the published note, the target price was lifted from HK$642.99 to HK$645.62 based on DCF, reflecting smooth progress in sac-TMT development. Near-term catalysts cited included the ASCENT-GYN readout around year-end, approval progress for sac-TMT in endometrial cancer, additional TroFuse Phase III data, and a planned Phase III study combining MK-2010 with sac-TMT. Even so, the latest trading suggests the rating upgrade has not offset short-term weakness in the name.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments